COLORADO SPRINGS, Colo.,
Jan. 5, 2015 /PRNewswire/ --
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce the International
release of 8 initial products that will be synergistically
produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active
and has cannabis production facilities.
The products are currently ready for pre-clinical studies,
self-medicating patient ailment usage, marketing release, sales and
distribution. The roll-out will involve Cannabis Science teams in
both Europe and California to work in tandem to share
information, send formulations to be produced in each respective
production facility and share patient indicators based on usage
metrics to scale demand, while collecting insightful data in each
geographical market appropriately. Different logistical
capabilities will be developed through internal management to
adequately produce, distribute and market products along with the
proper procurement of opt-in, informed consent patient data from
outcomes to establish Cannabis Science with a vertically integrated
product pipeline to accommodate international markets.
Cannabis Science will be announcing shortly where products are
available for purchase in each jurisdiction; initial cannabis
formulations will be focused on:
- Topical formulations for cancers
- Ingestible formulations for cancers, HIV/AIDS and other
indications
- Varied formulations for neurological disorders and other
indications depending on delivery methodology required
- Ingestible and topical formulations for chemotherapy side
effects, chronic pain, muscle problems, sleeping disorders, nausea,
ADHD, rheumatism, arthritis, infections, diabetes, manic
depression, fibromyalgia and other issues
- Topical formulations for rheumatism, fibromyalgia, arthritis,
eczema, sporting injuries, radiotherapy wounds, muscle and neck
pain, radiotherapy wounds, rheumatism, open wounds and sensitive
and irritated skin, various skin complaints, and wounds
The Cannabis Science Patient Access Center (PAC)
http://pac.cannabisscience.com, released in beta version, is now
available for patients to track usage and receive updates.
"With the proper distribution channels in place to reach large
ranges of patients in different prognosis situations, we intend on
releasing our cannabis formulations with specific support channels
and applications to provide consumers adequate insight into product
specifications, usage recommendations and the opt-in ability to
input a variety of sentiments across medical indicators for the
appropriate monitoring of effects. Our Scientific Advisory Board
and management team is working towards the development of a
vertically integrated model to standardize aforementioned practices
for multiple other jurisdictions and regulatory environments to
accommodate the growth of the sector," stated Mr. Raymond C. Dabney, Director, President &
CEO, Co-Founder, Cannabis Science, Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history
dating back thousands of years, and currently, there are a growing
number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The
Company works with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers and neurological
conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director,
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director,
COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-inc-cbis-to-release-8-initial-cannabis-based-products-synergistically-produced-distributed-and-marketed-across-california-spain-and-the-netherlands-for-pre-clinical-studies-and-immediate-self-medicating-p-300015686.html
SOURCE Cannabis Science, Inc.